Overview
Medical technology firm's Q1 revenue grew 2.5% yr/yr, missing analyst expectations
Adjusted EPS for Q1 increased 1.0% but missed analyst expectations
Company scheduled special stockholder meeting for merger vote with funds managed by Blackstone and TPG
Outlook
Hologic is not providing fiscal 2026 guidance due to pending acquisition by Blackstone and TPG
Result Drivers
SURGICAL SEGMENT - Revenue grew 8.7%, driven by increased sales from the acquired Gynesonics business and products like MyoSure and Fluent
BREAST HEALTH - Revenue rose 1.8%, supported by strong sales of Endomagnetics products
DIAGNOSTICS DECLINE - Revenue decreased 1.3%, impacted by lower sales of COVID-19 tests and legacy assays
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Miss | $1.05 bln | $1.07 bln (8 Analysts) |
Q1 Adjusted EPS | Miss | $1.04 | $1.09 (10 Analysts) |
Q1 EPS | $0.79 | ||
Q1 Adjusted Net Income | Miss | $235.50 mln | $247.62 mln (7 Analysts) |
Q1 Adjusted EBITDA | Miss | $330.40 mln | $338.50 mln (4 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 18 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Hologic Inc is $76.00, about 1.2% above its January 28 closing price of $75.10
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago
Press Release: ID:nBwbH1JNga
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)